Table 1 Inclusion and exclusion criteria by cohort

Acute Cohort

1. Aged <18 years at time of cancer diagnosis;

2. Diagnosed with a new malignancy;

3. Cancer treatment plan will require therapy with ≥1 dose of an anthracycline chemotherapy

4. Pre-anthracycline; echocardiograms to occur at the recruiting site;

5. Normal cardiac function prior to the initiation of anthracycline therapy (LVEF >55%).

1. Patients with significant congenital heart defects;

2. Patients who were previously treated with anthracycline chemotherapy or radiation to the chest.

Survivor Cohort

1. Aged <18 years at time of cancer diagnosis;

2. Previously diagnosed with cancer and currently in remission;

3. Patients whose prior treatment plan included therapy with ≥1 dose of anthracycline chemotherapy;

4. Patients who completed their final dose of anthracycline ≥3 years ago;

5. Patients who completed their final dose of a chemotherapy agent other than anthracycline ≥1 year ago;

6. Routinely followed at the recruiting site approximately every 12 months.

1. Prior allogeneic stem cell transplant;

2. Patients with significant congenital heart defects;

3. CMR: general contraindications for a contrast enhanced CMR, and patients who require anaesthesia for MRI (typically <6 years of age) will be excluded.